Emcure Pharma’s shares decline over 3% over block deal news
ADVERTISEMENT
Pune-based Emcure Pharmaceuticals Limited saw its share price decline 3.24% in today’s session at ₹1,349.70, after logging huge trade volumes. According to the counter on the NSE, 18.33 lakh worth ₹245.08 crore were traded. According to multiple reports, global investment firm BC Investments (Bain Capital) is likely to sell up to 2% of its equity through a block deal, at ₹1,296.51 per share. The block deal size is estimated at up to ₹493 crore.
The market capitalisation of the company stood at ₹25,589.36 crore. The 52-week high was at ₹1,519.90 per share, and the 52-week low was at ₹889.
According to the reported Q2 results for the current financial year, there was a revenue growth of 13% year-on-year to ₹2,270 crore, up from ₹2,002 crore in Q2FY25. As per their earnings call, the company highest quarterly profits of ₹251 crore, representing a 25% PAT growth. The domestic business grew by 10.6% YoY to ₹1,031 crore, which is led by strong performance across all key therapies. International markets maintained the growth momentum, up by 15.8% YoY, to ₹1,238 crore.
Emcure Pharma and Novo Nordisk India also announced a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India. “The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India,” the statement read. The company said that partnering with Novo is a much more lucrative opportunity to really grab market share and shape the market.
November 2025
The annual Fortune India special issue of India’s Best CEOs celebrates leaders who have transformed their businesses while navigating an uncertain environment, leading from the front.
“This partnership is part of Novo Nordisk India’s efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, semaglutide injection 2.4 mg, in India,” the press release stated.
At the time of reporting, the shares of Emcure Pharma were priced at ₹1,350.70, down by 3.11%.